Anil Aktas-Samur, PhD, on Identifying Low-Risk Smoldering Multiple Myeloma

January 11, 2022 By The ASCO Post Staff

Anil Aktas-Samur, PhD, of Dana-Farber Cancer Institute, discusses study findings on the genomic characterization of non-progressor smoldering multiple myeloma, results that may provide a molecular definition of the disease as well as its risk-driving features. Combining this low-risk model with current high-risk models may possibly improve clinical trials for patients with this early precursor to myeloma (Abstract 545).

 

Related Content